In addition, the clinical outcomes (disease-free survival rate and overall survival rate) of the TCGA breast cancer patients (including luminal A and B) with high expression levels of COPS5 appeared to be poorer (Supplementary Fig. 1a,b). This evidence concerns the gene COPS5 and breast carcinoma.